分化型甲状腺癌伴远处转移患者的生存预后:基于SEER人群的研究
基于美国SEER-17登记库(2010-2019年)2411例分化型甲状腺癌伴远处转移成人患者,随访中位62个月。生存树分析按疾病特异性生存识别出3个预后组(5年生存率92%、64%、41%),按总生存识别出4个预后组(5年生存率96%、84%、57%、31%)。患者年龄、肺转移和肿瘤大小对两种生存均有重要影响。
要点
- 疾病特异性生存的生存树首次分割为诊断年龄(≤57岁 vs ≥58岁)。
- 3个疾病特异性生存预后组的5年生存率分别为92%、64%、41%(p < 0.001)。
- 4个总生存预后组的5年生存率分别为96%、84%、57%、31%(p < 0.001)。
核心结论
- 本研究识别了分化型甲状腺癌伴远处转移患者的不同预后组,并强调患者年龄、肺转移和肿瘤大小对疾病特异性生存和总生存均有重要作用。
- 这些发现有助于该研究不足人群中风险分层和治疗决策。
研究设计与样本
- 从美国SEER-17癌症登记库(2010-2019年)识别成人分化型甲状腺癌伴远处转移患者。
- 队列共2411例患者,随访中位62个月。
- 分析采用Cox比例风险回归、生存树和随机生存森林;基于随机生存森林评估患者和肿瘤因素对疾病特异性生存和总生存的相对重要性。
主要发现
- 最常见组织病理学亚型为甲状腺乳头状癌(86.0%),最常见远处转移部位为肺(33.7%)和骨(18.9%)。
- Cox比例风险模型显示生存与以下因素显著相关:患者年龄(p < 0.001)、肿瘤大小(p < 0.01)、远处转移部位(p < 0.05)。
- 疾病特异性生存的生存树识别出3个预后组,5年生存率分别为92%、64%、41%(p < 0.001)。
- 总生存的生存树识别出4个预后组,5年生存率分别为96%、84%、57%、31%(p < 0.001)。
- 疾病特异性生存和总生存的生存树首次分割均为诊断年龄(≤57岁 vs ≥58岁),后续分割基于肺转移有无、肿瘤大小(≤4 cm vs >4 cm)和患者年龄。
关键数值与推荐
- 疾病特异性生存预后组5年生存率:92%、64%、41%(p < 0.001)。
- 总生存预后组5年生存率:96%、84%、57%、31%(p < 0.001)。
- Cox模型显著性:患者年龄p < 0.001,肿瘤大小p < 0.01,远处转移部位p < 0.05。
临床怎么用
- 作者认为这些发现有助于该研究不足人群的风险分层和治疗决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: For patients with thyroid cancer, distant metastasis is a significant predictor of poor outcome. Since distant metastasis occurs in less than 10% of patients with differentiated thyroid cancer, correlates of survival in this vulnerable patient population remain understudied. This study aimed to identify prognostic groups among patients with differentiated thyroid cancer and distant metastases and to determine the role of, and interactions between, patient and tumor characteristics in determining survival. Methods: We identified adult patients diagnosed with differentiated thyroid cancer with distant metastases from the U.S. SEER-17 cancer registry (2010-2019). Analyses were performed using Cox proportional hazards regression, survival trees, and random survival forest. Relative importance of patient and tumor factors important for disease-specific and overall survival was assessed based on the random survival forest analyses. Results: Cohort consisted of 2411 patients with differentiated thyroid cancer with distant metastases followed for a median of 62 months. Most common histopathologic subtype (86.0%) was papillary thyroid cancer, and the most common sites of distant metastasis were the lungs (33.7%) and bone (18.9%). Cox proportional hazards model illustrated significant associations between survival and the following: patient age (p < 0.001), tumor size (p < 0.01), and site of distant metastasis (p < 0.05). Survival tree analyses identified three distinct prognostic groups based on disease-specific survival (DSS) (5-year survival of the prognostic groups was 92%, 64%, and 41%; p < 0.001) and four distinct prognostic groups based on overall survival (OS) (5-year survival of the prognostic groups was 96%, 84%, 57%, and 31%; p < 0.001). The first split in the survival trees for DSS and OS was by age at diagnosis (≤57 years vs. ≥58 years) with subsequent splits based on presence/absence of lung metastases, tumor size (≤4 cm vs. >4 cm), and patient age. A total of 558 patients (23.1%) died from thyroid cancer, and 757 patients (31.4%) died from all causes during the study period. Conclusions: This study identifies distinct prognostic groups for patients with differentiated thyroid cancer with distant metastases and highlights the importance of patient age, lung metastases, and tumor size for determining both disease-specific and overall survival. These findings inform risk stratification and treatment decision-making in this understudied patient population.
引用
- Chen DW, Carr G, Worden FP, et al. Survival Prognostication in Patients with Differentiated Thyroid Cancer and Distant Metastases: A SEER Population-Based Study. Thyroid. 2024. PMID: 38757633. doi:10.1089/thy.2023.0709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。